Tenax Therapeutics Inc (TENX)

[lynne351]

Chris Stern Blog - http://eshareholderforum.com/oxbo/Chris_Stern/

Trading on the NASDAQ
January 13, 2010, 7:54 pm

The New Year is off to a great start for Oxygen Biotherapeutics, Inc. It began with the achievement of one of our major near-term goals – to get our stock listing off of the Bulletin Board and onto a major exchange. Our shares will be trading on the NASDAQ starting this Friday, January 15. I plan to be at the Exchange to ring the opening bell on Jan. 22. Watch for video of that on our website, or be at Times Square in New York City for viewing on the big screen.

Having our shares listed on the NASDAQ will give our company visibility to a broad range of potential investors who could not or would not have considered investing in our stock when it was on the Bulletin Board. Most of the big institutional investors (mutual funds, pension funds, etc.) will not buy penny stocks (which we were pre-split) nor buy shares that are not traded on a major exchange. Likewise, many retail brokerage firms cannot recommend such stocks to their clients. Being listed on the NASDAQ could lead to greater interest in our common stock by the broader financial community and the investing public. This re-listing is an important opportunity to position our company where we believe it belongs. It will give us the potential financial strength needed to become a company with multiple products in various development stages.

Speaking of multiple products, at today’s OneMedForum conference, I mentioned our plans for new product developments. I think some of those plans are pretty exciting.

First of all, we’re adding an additional pillar to our business strategy – veterinary products. Our research has come up with an animal wound-care product line for topical application. It takes the healing ability of Oxycyte™ in a gel form and makes it available to apply to pets, farm animals, etc. Because it is a topical product line for animals, we believe we can bring it to market very quickly. If you think about how much Americans spend on their pets, you can see that the potential could be very significant. Our goal is to have these products, which we have tentatively named OxyBioPet, on the market this year.

We plan to follow that with a second veterinary product line, which we are initially calling OxyBioVet. This would be an intravenous Oxycyte emulsion veterinarians could use to carry oxygen to an animal’s heart, brain or other organs. While I am not willing, right now, to predict the timing for a market launch, the requirements for animal products are far less restrictive than for humans.

At the same investor conference, I also briefly mentioned our plans to expand our cosmetic product line this year. We are targeting this spring to roll out our Dermacyte Eye Cream. It is formulated for those fine line wrinkles around the eyes. We will also launch another formulation as a face lotion, and a repackaged version of our cosmetic concentrate gel, which we recently tested in blister packs via on-line sales. As a fourth product, we’re considering the Dermacyte Oxygenating Solution (DOS). Think of it as a perfluorocarbon liquid in its basic, clear form – not a gel or a cream but the PFC liquid with its ability to capture oxygen from the air and carry it through the outer skin layer.

Meanwhile, our TBI clinical trials are under way. It’s not likely that we will be providing any additional information until some time after the first cohort has been treated and the results analyzed. While enrollment of the first patient was delayed for reasons previously explained, I’m confident that we’re on a time line to complete the trial in the targeted 12 to 18 months.

2010 began with a major milestone and I expect the whole year to bring others. Thank you for your support. Stay tuned; stay healthy, wealthy, and safe. God bless.